Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8964019 | Surgical Pathology Clinics | 2018 | 8 Pages |
Abstract
Lung cancer diagnosis and ancillary testing are increasingly relying on cytology and small biopsy specimens obtained via minimally invasive means. Paired with traditional immunohistochemical characterization of tumors, biomarker testing and comprehensive genomic profiling are becoming essential steps in the workup of lung cancer to identify targetable alterations and guide optimal therapy selection. Recent advances in immune checkpoint inhibitor therapy have led to an increasingly complex and unresolved landscape for tumor PD-L1 testing. The prevalence and importance of lung cancer cytology specimens are growing, with more required by the cytopathologist in directing the care of patients with lung cancer.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Paul A. MD, PhD,